Products with Cardioprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1049 | Hydroxysafflor yellow A |
| Hydroxysafflor yellow A(H-A) possesses hepatoprotective, anti-inflammatory, and anti-tumor activities, it can effectively protect the liver of rats from long-term alcohol injury, which relates with the enhanced antioxidant capacity of liver tissues and inhibition of TGF-β1 expression, it also inhibited angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. H-A also can provide protection to H9c2 cardiomyocytes against A/R-induced apoptosis by the upregulation of HO-1 expression through the PI3K/Akt/Nrf2 signaling pathway. | |
| BCN1062 | Pseudoginsenoside F11 |
| Pseudoginsenoside F11, a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5. It possesses significant neuroprotective activity, has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice; it also antagonizes the development of analgesia tolerance to morphine and blocks the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC. | |
| BCN1063 | Ginsenoside Rb1 |
| Ginsenoside Rb1 is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, cardioprotective, anti-obesity, anti-inflammatory, and anti-oxidative actions. Ginsenoside Rb1 can up-regulate the expression of GLUTs in adipose tissue, in addition to activate insulin signalling pathway, and may effectively ameliorate the progression of asthma through Relegating Th1/Th2. It inhibited Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM, activated Akt, phosphorylating GSK-3β and inhibited mPTP opening. | |
| BCN1073 | Ginsenoside Re |
| Ginsenoside Re is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including anti-diabetic, vasorelaxant, antihyperlipidemic, anti-ischemic, angiogenic, antioxidant, and anti-inflammation actions. It also exhibits potent neuroprotective effects against neuroinflammation in a murine model of ALS. Re increases HCAEC outward current via SKCa channel activation; it also increases the proliferation of CD4+ T cells with decreases cell death, and enhances viability of CD4+T cells through the regulation of IFN-γ-dependent autophagy activity. | |
| BCN1080 | Panaxadiol |
| Panaxadiol, an anti-hepatitis B virus inhibitor, exhibits anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities. It inhibits Ca2+ channels, decreasing channel open time and open state probability in vitro and displaying anti-arrhythmic potential. Panaxadiol selectively interferes with the cell cycle in human cancer cell lines, it inhibits DNA synthesis in a dose-dependent manner with IC50 values ranging from 0.8 to 1.2 μM in SK-HEP-1 cells and HeLa cells, it selectively elevates p21WAF1/CIP1 levels and thereby arrests the cell cycle at G1/S phase by down-regulating Cyclin A–Cdk2 activity. | |
